0001104659-26-035251
SEC filingQuoin Pharmaceuticals, Ltd. reported a net loss of $15.8 million for the fiscal year ended December 31, 2025, compared to a net loss of $9.0 million in the prior year. The increased loss was driven by a significant rise in research and development expenses to $9.8 million, up from $3.6 million in 2024, as the company advanced its lead product candidate QRX003 into late-stage clinical testing for Netherton Syndrome. General and administrative expenses also increased to $6.5 million. The company generated no revenue, consistent with its pre-commercial stage. Cash used in operating activities was $13.5 million. Management has concluded there is substantial doubt about the company's ability to continue as a going concern, citing an accumulated deficit of $71.0 million and the need for additional capital to fund operations and complete clinical development.
Quoin Pharmaceuticals reported a comprehensive loss of $15.8 million for the fiscal year ended December 31, 2025, a significant increase from the $9.0 million loss in the prior year. This deterioration was primarily driven by a 172% increase in research and development expenses, which rose to $9.8 million from $3.6 million in 2024, reflecting accelerated clinical development activities for lead candidate QRX003. General and administrative expenses also increased by 9.5% to $6.5 million. The company generated no revenue during the period, consistent with its development-stage status. Other income of $486,000 provided partial offset to operating losses, consisting primarily of interest income from investments.
The company has not generated any revenue from product sales since inception. All operations are funded through equity financings and investment income. The document explicitly states: "To date, no products have been commercialized and no revenue has been generated." The business model remains entirely dependent on successful clinical development and regulatory approval of product candidates before any revenue generation can occur.
With no revenue, traditional margin analysis is not applicable. The company's operating loss margin, calculated as operating expenses relative to its asset base, reflects the substantial investment in clinical development. Operating expenses totaled $16.3 million for the year, with research and development comprising 60% of this total. The significant increase in R&D spending demonstrates the company's focus on advancing QRX003 through clinical trials, though this has substantially increased net losses.
Net cash used in operating activities was $13.5 million for the year ended December 31, 2025. The company reported cash and cash equivalents of $3.8 million and investments of $14.9 million at year-end, for total current assets of $20.0 million. Total assets were $20.4 million, while total liabilities stood at $7.3 million, resulting in shareholders' equity of $13.1 million. Cash flows from financing activities provided $18.0 million, primarily from the October 2025 private placement and warrant exercises. The company's accumulated deficit reached $71.0 million, and management has concluded there is substantial doubt about the company's ability to continue as a going concern without additional financing.
The company's future depends on successful clinical development of QRX003 for Netherton Syndrome and other rare diseases. Management plans to complete late-stage clinical testing and seek regulatory approvals in the U.S., Europe, and Japan. The company must raise additional capital to fund operations, with management noting that funding may not be available on acceptable terms or at all. Key risk factors include clinical trial failures, regulatory delays, competition from other developers, and the need to establish commercial infrastructure if products are approved. The company has nine commercial partnerships spanning 61 countries for QRX003 outside its core territories.